Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $73.38

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned an average recommendation of “Buy” from the ten research firms that are presently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on the stock in the last year is $73.38.

A number of equities analysts have weighed in on JSPR shares. JMP Securities restated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $68.00 price target on shares of Jasper Therapeutics in a research note on Monday, December 23rd. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Finally, BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Samsara BioCapital LLC increased its holdings in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after acquiring an additional 59,642 shares during the last quarter. Ally Bridge Group NY LLC increased its stake in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares during the last quarter. Braidwell LP acquired a new stake in shares of Jasper Therapeutics during the third quarter worth $9,091,000. FMR LLC bought a new position in shares of Jasper Therapeutics in the 3rd quarter worth about $722,000. Finally, Wellington Management Group LLP acquired a new position in shares of Jasper Therapeutics in the 3rd quarter valued at about $447,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $19.27 on Wednesday. Jasper Therapeutics has a 1-year low of $6.50 and a 1-year high of $31.01. The company has a market capitalization of $289.07 million, a price-to-earnings ratio of -4.07 and a beta of 2.18. The business has a 50-day moving average of $22.07 and a 200-day moving average of $20.54.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.